Serum Neuron-Specific Enolase Levels Predict the Efficacy of First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations

摘要

Our study aimed to determine the role of serum neuron-specific enolase (NSE) in predicting epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) response in EGFR mutant non-small cell lung cancer (NSCLC). Patients with elevated serum NSE levels had significantly shorter progression-free survival (PFS) and overall survival (OS) after first-line EGFR TKI treatment. Our study suggests potential use of NSE for predicting EGFR TKI response and prognosis.